Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
28.44
+1.12 (4.10%)
At close: Aug 1, 2025, 4:00 PM
28.24
-0.20 (-0.69%)
After-hours: Aug 1, 2025, 7:50 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 16 analysts that cover Revance Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $86.94, which forecasts a 205.70% increase in the stock price over the next year. The lowest target is $34 and the highest is $140.
Price Target: $86.94 (+205.70%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 6 |
| Buy | 8 | 8 | 8 | 10 | 9 | 9 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15 | 15 | 15 | 17 | 15 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $80 | Strong Buy | Initiates | $80 | +181.29% | Jul 28, 2025 |
| Wedbush | Wedbush | Hold Maintains $35 → $34 | Hold | Maintains | $35 → $34 | +19.55% | Jul 14, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $65 → $55 | Buy | Maintains | $65 → $55 | +93.39% | Jul 14, 2025 |
| Wells Fargo | Wells Fargo | Buy Maintains $88 → $65 | Buy | Maintains | $88 → $65 | +128.55% | Jul 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $64 | Strong Buy | Reiterates | $64 | +125.04% | Jun 20, 2025 |
Financial Forecast
Revenue This Year
665.02M
from 560.23M
Increased by 18.70%
Revenue Next Year
842.97M
from 665.02M
Increased by 26.76%
EPS This Year
-5.00
from -6.29
EPS Next Year
-3.48
from -5.00
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 701.8M | 1.1B | 1.9B | ||
| Avg | 665.0M | 843.0M | 1.2B | ||
| Low | 620.0M | 651.1M | 779.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 25.3% | 60.7% | 119.7% | ||
| Avg | 18.7% | 26.8% | 47.5% | ||
| Low | 10.7% | -2.1% | -7.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.85 | -0.86 | 1.84 | ||
| Avg | -5.00 | -3.48 | -0.72 | ||
| Low | -6.89 | -5.27 | -3.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.